A two year clinical, immunological and gut-brain-axis prospective study to predict treatment response to cladribine tablets in relapsing-remitting multiple sclerosis.

van Pamelen J, van Ansenwoude CMJ, Miguélez Sánchez M, Spijkerbosch L, Rodriguez-Mogeda C, van Olst L, van der Pol SMA, Boon ML, Koel-Simmelink MJA, van Seeters T, et al.